Desmaele Sara, Putman Koen, De Wit Liesbet, Dejaeger Eddy, Gantenbein Andreas R, Schupp Wilfried, Steurbaut Stephane, Dupont Alain G, De Paepe Kristien
Research Group Clinical Pharmacology and Clinical Pharmacy (KFAR), Centre for Pharmaceutical Research (CePhar), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium.
Interuniversity Centre for Health Economics Research (ICHER), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium.
Clin Neurol Neurosurg. 2016 Sep;148:96-104. doi: 10.1016/j.clineuro.2016.07.007. Epub 2016 Jul 4.
The use of medication plays an important role in secondary stroke prevention and treatment of post-stroke comorbidities. The Collaborative Evaluation of Rehabilitation in Stroke across Europe (CERISE) was set up to investigate the inpatient stroke rehabilitation process in four centres, each in a different European country: Belgium, Germany, United Kingdom and Switzerland.
Patients' medication use 5 years post-stroke was compared between countries. Focus was put on cerebrovascular secondary prevention, including (a) adequate antithrombotic treatment, (b) treatment of cardiovascular comorbidities and diabetes, and (c) the use of lipid-lowering drugs; as well as on the treatment of stroke-related disorders such as depression, anxiety and pain.
Medication data were available for 247 patients. Data about depression and anxiety were available for 233.
There were no significant differences between the four centres in antithrombotic treatment and in the treatment of cardiovascular comorbidities and diabetes. However, significantly more patients from the UK were treated with lipid-lowering drugs compared to Belgian patients. Significant differences were also observed between the centres in the prevalence and treatment of depression. More Belgian patients suffered from depression compared to German patients and significantly more Belgian patients took antidepressants than patients in Germany. This was in contrast to the prevalence and treatment of anxiety and pain, for which no significant differences between the centres were seen. Related to pain treatment, it was observed that almost 40% of all patients suffering from pain, used no specific medication.
药物治疗在卒中二级预防及卒中后合并症的治疗中起着重要作用。欧洲卒中康复协作评估（CERISE）旨在调查四个中心的住院卒中康复过程，每个中心位于不同的欧洲国家：比利时、德国、英国和瑞士。
比较各国卒中后5年患者的用药情况。重点关注脑血管二级预防，包括（a）充分的抗栓治疗，（b）心血管合并症和糖尿病的治疗，以及（c）降脂药物的使用；同时关注卒中相关疾病如抑郁、焦虑和疼痛的治疗。
247例患者有用药数据。233例患者有抑郁和焦虑数据。
四个中心在抗栓治疗以及心血管合并症和糖尿病的治疗方面无显著差异。然而，与比利时患者相比，英国接受降脂药物治疗的患者明显更多。各中心在抑郁患病率及治疗方面也存在显著差异。与德国患者相比，更多比利时患者患有抑郁症，且服用抗抑郁药的比利时患者明显多于德国患者。这与焦虑和疼痛的患病率及治疗情况形成对比，各中心在这方面未见显著差异。在疼痛治疗方面，观察到几乎40%的疼痛患者未使用特定药物。
